Nova Mentis Life Science Corp. is a Canada-based biotechnology company. The Company is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The Company operates in one segment, being engaged in research and development of psilocybin in Canada through the Company’s subsidiaries, Nova Mentis Biotech Corp. and Pilz Bioscience Corp. Nova Mentis Biotech Corp. and Pilz Bioscience Corp. is engaged in psilocybin research and development. Nova Mentis Biotech Corp. is engaged in the development of investigating anti-inflammatory effects of psilocybin in neurometabolic indications, such as obesity and diabetes. Pilz Bioscience Corp. is engaged in developing medicinal psychedelics for neuroinflammatory conditions with cognitive components and high unmet therapeutic needs.
Metrics to compare | NOVA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNOVAPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.4x | −3.9x | −0.6x | |
PEG Ratio | −0.03 | 0.01 | 0.00 | |
Price/Book | −1.4x | 0.2x | 2.6x | |
Price / LTM Sales | - | 3.1x | 3.2x | |
Upside (Analyst Target) | - | 195.3% | 47.1% | |
Fair Value Upside | Unlock | −17.1% | 7.1% | Unlock |